Mufemilast Phase 2 Data May Partially De-Risk Palisade Bio's PALI-2108

Hemay’s Phase 2 mufemilast data suggest that oral PDE4 inhibition can drive biologic-range remission rates in moderate-to-severe ulcerative colitis. This class-level evidence may partially de-risk Palisade Bio’s PALI-2108.